How can we accelerate Europe’s transition to a circular battery economy? Within the Secure Battery Passport Demonstrator (SeBaPaD) project, TNO and NXP have developed a secure and interoperable ...
Thrust Zone on MSN
Samarth E-Mobility full-stack EV technology platform built in India
Marking a significant milestone in India’s electric mobility journey, Samarth E-Mobility Pvt. Ltd., a technology-first, innovation-led electric mobility company, today announced the development and ...
The FlexCombo 2.0 is an AC Block designed to support the evolving requirements of power systems, including grid stability, regulatory compliance, and scalable project development.
The Chinese manufacturer said its new three residential battery lines support a depth of discharge of 90% and deliver over 6,000 cycles.
Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence ...
Bristol Myers Squibb (BMS) is confident pivotal readouts from its core pipeline will drive profits towards 2030 despite looming patent expiries for revenue leaders Opdivo and Eliquis, says CEO ...
Nearly 4,500 Tesla Model 3 and Model Y owners in South Korea have complained about battery malfunctions that prevent charging. The problem, which primarily affects 2021 models, has drawn the scrutiny ...
PXI/PXIe solution offers scalable, modular design for faster development cycles and lower total cost of ownership, plus improved safety Pickering Interfaces, the leading supplier of modular signal ...
Add Silicon Canals to your Google News feed. PXI/PXIe solution offers scalable, modular design for faster development cycles and lower total cost of ownership, plus improved safety CLACTON-ON-SEA, ...
Beecher Manufacturing Services acquired BMS Manufacturing Co. in Watkins Glen, New York. The acquisition will help Ward Apparatus, another Beecher company, increase fire truck production. The ...
Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain Capital-led financing as part of the Big Pharma’s ambitious cost-cutting drive.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results